Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Free Cash Flow data on file, last reported at -$22.2 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 89.0% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was -$107.9 million, a 101.9% decrease from a year earlier, with the FY2025 full-year figure at -$97.4 million, down 59.19% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$22.2 million, down from -$17.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for WHWK reached as high as -$8.0 million in Q3 2022 and fell as low as -$53.6 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$17.1 million across 5 years, with a median of -$14.8 million in 2025.
• Across the five-year window, Free Cash Flow jumped 54.0% in 2022 and slumped 407.07% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$11.7 million in 2022, then grew by 18.56% to -$9.5 million in 2023, then slumped by 79.27% to -$17.1 million in 2024, then decreased by 0.94% to -$17.2 million in 2025, then fell by 28.86% to -$22.2 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$22.2 million in Q1 2026, -$17.2 million in Q4 2025, and -$14.8 million in Q3 2025.